医学
队列
临床终点
内科学
成纤维细胞生长因子受体
转移性尿路上皮癌
成纤维细胞生长因子受体1
肿瘤科
置信区间
胃肠病学
成纤维细胞生长因子
癌症
尿路上皮癌
受体
临床试验
膀胱癌
作者
Andrea Necchi,Damien Pouessel,Raya Leibowitz‐Amit,Shilpa Gupta,Aude Fléchon,Jesús García-Donás,Mehmet Asım Bilen,Philip R. Debruyne,Matthew I. Milowsky,Terence W. Friedlander,Massimo Di Maïo,Aidan G. Gilmartin,Xiangcheng Li,M L Veronese,Yohann Loriot
标识
DOI：10.1016/j.annonc.2023.10.794
摘要
Fibroblast growth factor receptor 3 (FGFR3) alterations are oncogenic drivers of urothelial carcinoma (UC). Pemigatinib is a selective, oral inhibitor of FGFR1-3 with antitumor activity. We report the efficacy and safety of pemigatinib in the open-label, single-arm, phase II study of previously treated, unresectable or metastatic UC with FGFR3 alterations (FIGHT-201; NCT02872714).
科研通智能强力驱动
Strongly Powered by AbleSci AI
带头大哥
爱静静
寻道图强
Billy
yangguang2000
双黄
平常的毛豆
嗯哼
杳鸢
妖娃娃
苹果丑
从容芮
ppg123
tuanheqi
科目三
秀丽烨霖
美好斓
membrane
Yziii
CodeCraft
皖公网安备34019202002308
